USARx offers the following ways to purchase this medication. Choose the Best option for you!
No52% of Medicare Part D and Medicare Advantage plans cover this drug, so it's pretty much a toss-up.
It depends. Which coverage stage are you in? Click on a tab below…
$5 – $125
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your lumigan prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about bimatoprost ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Lumigan.In Summary
Common side effects of Lumigan include: hypertrichosis of eyelid. See below for a comprehensive list of adverse effects.For the Consumer
Applies to bimatoprost ophthalmic: ophthalmic solution
Along with its needed effects, bimatoprost ophthalmic (the active ingredient contained in Lumigan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking bimatoprost ophthalmic:
Some side effects of bimatoprost ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to bimatoprost ophthalmic: ophthalmic solutionGeneral
The most frequently reported adverse reactions were eyelash growth, conjunctival hyperemia, and ocular pruritus.Ocular
Very common (10% or more): Growth of eyelashes (up to 45%), conjunctival hyperemia (up to 44%), ocular pruritus (up to 15%)
Common (1% to 10%): Allergic conjunctivitis, asthenopia, blepharitis, blurred vision, cataract, conjunctival edema, conjunctival hemorrhage, corneal erosion, dry eye, eye discharge, eye irritation, eye pain, eye pruritus, eyelash darkening, eyelid pruritus, foreign body sensation, increased iris pigmentation, lacrimation increased, ocular burning, ocular dryness, ocular irritation, photophobia, punctate keratitis, superficial punctate keratitis, tearing, visual disturbance, worsening of visual acuity
Uncommon (0.1% to 1%): Blepharospasm, eyelid edema, eyelid margin crusting, eyelid retraction, iris hyperpigmentation, iritis, retinal hemorrhage, uveitis
Rare (0.01% to 0.1%): Corneal calcification
Frequency not reported: Blepharal pigmentation, cystoid macular edema, eye edema, eyelash changes, eyelid sulcus deepening, intraocular inflammation, macular edema, signs/symptoms of eye allergy
Postmarketing reports: Enophthalmos
Corneal calcification occurred in patients with significant corneal damage using formulations containing phosphate.Dermatologic
Common (1% to 10%): Eyelid erythema, hirsutism, hypertrichosis, periocular skin hyperpigmentation, periorbital erythema, pigmentation of periocular skin, skin hyperpigmentation
Uncommon (0.1% to 1%): Abnormal hair growth, dry skin, madarosis, pruritus
Frequency not reported: Lid changes, periorbital changes, pigmentation, signs/symptoms of allergic dermatitisImmunologic
Common (1% to 10%): Colds, infectionsRespiratory
Common (1% to 10%): Upper respiratory tract infections
Frequency not reported: Asthma, asthma exacerbation, chronic obstructive pulmonary disease (COPD) exacerbation, dyspnea
Postmarketing reports: Asthma-like symptomsNervous system
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Dizziness, vertigoLocal
Common (1% to 10%): Instillation site irritationHepatic
Common (1% to 10%): Abnormal liver function testsOther
Uncommon (0.1% to 1%): AstheniaCardiovascular
Common (1% to 10%): HypertensionGastrointestinal
Uncommon (0.1% to 1%): NauseaPsychiatric
Uncommon (0.1% to 1%): DepressionHypersensitivity
Frequency not reported: Hypersensitivity, hypersensitivity reaction
November 24, 2020
December 2, 2020
November 15, 2020
December 2, 2020
December 1, 2020
October 19, 2020